Body_weight

MOTS-c partially protects against skeletal muscle deterioration in C26 cachexia.

BACKGROUND

Cancer cachexia is a multifactorial metabolic syndrome marked by progressive skeletal muscle loss, reduced function, and increased mortality. Mitochondrial dysfunction is a key driver of this phenotype. MOTS-c, a mitochondrial-derived peptide that regulates metabolic homeostasis and mimics exercise signaling, may...

🗓️ 2026-06-10
Read MoreMOTS-c partially protects against skeletal muscle deterioration in C26 cachexia.

Novel Long-Acting Ghrelin Analogue PEP-064 Restores Energy Balance in C26 and Lewis Lung Carcinoma-Induced cachexia in Mice.

BACKGROUND

Cancer cachexia is a debilitating syndrome marked by involuntary weight loss resulting from reduced food intake and intricate metabolic reprogramming. Despite its high prevalence, cancer cachexia remains undertreated, with a lack of effective and approved pharmacotherapies. Ghrelin has emerged as...

🗓️ 2026-06-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreNovel Long-Acting Ghrelin Analogue PEP-064 Restores Energy Balance in C26 and Lewis Lung Carcinoma-Induced cachexia in Mice.

Combined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

BACKGROUND

Cancer cachexia is associated with rapid body wasting and cardiac dysfunction. Bisoprolol (BIS) and megestrol acetate (MA) improve selected cachexia phenotypes in the Yoshida AH-130 model, but their combined effects are not defined. We tested reduced-dose combined treatment of BIS...

🗓️ 2026-05-23
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCombined Bisoprolol and Megestrol Acetate Improves Survival and Preserves Cardiac Performance in a Rat Model of Cancer Cachexia.

Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

BACKGROUND

In a recent Phase 2 trial in patients with cancer cachexia, the anti-GDF-15 antibody ponsegromab resulted in increased body weight, appetite, muscle mass and physical activity. This study provides compelling evidence that targeting the GDF-15 pathway may offer a viable...

🗓️ 2026-05-13
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.

Moderate Aerobic Training Causes Muscle Wasting in a DMBA-Induced Sarcoma Rat Model.

Cancer cachexia, characterized by severe body weight loss, negatively affects patient quality of life and survival. Although moderate exercise benefits healthy and chronically ill individuals, and the effect of exercise in cachexia generally appears beneficial, conflicting results have been reported...

🗓️ 2026-03-14
📰 Publication: International Journal Of Molecular Sciences
Read MoreModerate Aerobic Training Causes Muscle Wasting in a DMBA-Induced Sarcoma Rat Model.

A Novel Mouse Model to Identify Antigen-Specific Immune Responses in Pancreatic Cancer Cachexia.

BACKGROUND

Pancreatic Ductal Adenocarcinoma (PDAC) has a dismal five-year survival rate of 13% and is closely associated with cachexia. Cancer cachexia is a multifactorial syndrome characterized by irreversible wasting of skeletal muscles, fat loss and systemic inflammation. While cachexia is known...

🗓️ 2026-02-27
Read MoreA Novel Mouse Model to Identify Antigen-Specific Immune Responses in Pancreatic Cancer Cachexia.

Cancer Cachexia Prevalence Is Underestimated in Medical Records of Patients in a Regional Tertiary Hospital.

BACKGROUND

Widespread lack of awareness and limited real-world prevalence evidence have impeded cachexia care and research. We hypothesized that healthcare professionals may identify the term cachexia, leading to International Classification of Diseases (ICD) coding for this term, with or without records...

🗓️ 2026-02-18
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCancer Cachexia Prevalence Is Underestimated in Medical Records of Patients in a Regional Tertiary Hospital.

Glucagon Like Peptide-1 Receptor Agonists for Sarcopenia and Muscle Wasting Disorders: A Systematic Review of Efficacy and Mechanisms.

Muscle wasting disorders, including sarcopenia and skeletal muscle atrophy, are increasingly prevalent among older adults and those with metabolic comorbidities. Sarcopenia, a progressive age-associated condition, involves the decline in skeletal muscle mass, strength, and physical performance, affecting millions of people...

🗓️ 2025-12-16
📰 Publication: Aging And Disease
Read MoreGlucagon Like Peptide-1 Receptor Agonists for Sarcopenia and Muscle Wasting Disorders: A Systematic Review of Efficacy and Mechanisms.

From Symptom to Outcome: Defining Clinically Meaningful Patient-Reported Appetite Loss in Non-Small-Cell Lung Cancer.

BACKGROUND

Appetite loss is a common and distressing symptom in non-small-cell lung cancer (NSCLC), driven by both treatment side effects and disease progression. It often leads to unintended weight loss and cancer cachexia, significantly impairing patients' quality of life and survival....

🗓️ 2025-12-04
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreFrom Symptom to Outcome: Defining Clinically Meaningful Patient-Reported Appetite Loss in Non-Small-Cell Lung Cancer.

3D deep learning-based muscle volume quantification from thoracic CT as a surrogate for DXA-Derived appendicular muscle mass in older adults.

BACKGROUND

In order to identify patients with sarcopenia, the use of routine imaging could provide valuable support. One of the most common radiological examinations, especially in geriatric inpatient care, is CT thoracic imaging. Therefore, it would be desirable to generate muscle...

🗓️ 2025-10-21
📰 Publication: Aging Clinical And Experimental Research
Read More3D deep learning-based muscle volume quantification from thoracic CT as a surrogate for DXA-Derived appendicular muscle mass in older adults.

CSE/H 2S/SESN2 Signalling Mediates the Protective Effect of Exercise Against Immobilization-Induced Muscle Atrophy in Mice.

Hydrogen sulphide (H 2S), a gasotransmitter synthesized by cystathionine-γ-lyase (CSE), exhibits antioxidant properties and may mimic exercise-induced muscle protection. However, its mechanistic role in muscle atrophy and exercise intervention remains unclear. Six-month-old male wild-type (WT) and SESN2 knockout (SESN2 -/-)...

🗓️ 2025-10-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCSE/H 2S/SESN2 Signalling Mediates the Protective Effect of Exercise Against Immobilization-Induced Muscle Atrophy in Mice.

Sex-specific survival but not tissue wasting in the KPP mouse model of pancreatic cancer-induced cachexia.

Cancer cachexia, a multifactorial condition resulting in muscle and adipose tissue wasting, reduces the quality of life of many people with cancer. Cachexia is highly prevalent in people with pancreatic ductal adenocarcinoma (PDAC), and many animal models of pancreatic cancer...

🗓️ 2025-09-30
📰 Publication: Journal Of Applied Physiology
Read MoreSex-specific survival but not tissue wasting in the KPP mouse model of pancreatic cancer-induced cachexia.

hUC-MSCs and derived exosomes attenuate DEX-induced muscle atrophy through modulation of estrogen signaling pathway.

Sarcopenia, a multifactorial syndrome characterized by progressive loss of skeletal muscle mass and strength, combined with impaired physical function, is associated primarily with aging but also driven by chronic inflammation, immobility, and endocrine dysregulation. It leads to increased risks of...

🗓️ 2025-08-02
Read MorehUC-MSCs and derived exosomes attenuate DEX-induced muscle atrophy through modulation of estrogen signaling pathway.

GDF15: from biomarker to target in cancer cachexia.

Most patients with advanced cancer suffer from cachexia, a complex metabolic disorder characterized by unintentional body weight loss that diminishes their quality of life and reduces the effectiveness of therapies. Currently, effective treatments for cachexia remain elusive. Growth differentiation factor...

🗓️ 2025-07-09
📰 Publication: Trends In Cancer
Read MoreGDF15: from biomarker to target in cancer cachexia.

GL261 glioblastoma induces delayed body weight gain and stunted skeletal muscle growth in young mice.

The survival rate for children and adolescents has increased to over 85%. However, there is limited understanding of the impact of pediatric cancers on muscle development and physiology. Given that brain tumors alone account for 26% of all pediatric cancers,...

🗓️ 2025-04-18
📰 Publication: American Journal Of Physiology-Regulatory Integrative And Comparative Physiology
Read MoreGL261 glioblastoma induces delayed body weight gain and stunted skeletal muscle growth in young mice.

Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.

Cancer cachexia presents a significant challenge, but the ghrelin agonist anamorelin shows promise as a potential treatment. This study examined whether the baseline systemic inflammatory response (SIR) (measured by the modified Glasgow Prognostic Score [mGPS]), low BMI or greater weight...

🗓️ 2025-02-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAnamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!